Rockefeller Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Rockefeller Capital Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.4K	Buy	665 +532	+400%	+$8.57K	﹤0.01%	3864
2025 Q4	$2.15K	Buy	+133	New	+$1.76K	﹤0.01%	4302
2023 Q1	–	Sell	-1,323	Closed	-$8K	–	2988
2022 Q4	$8K	Hold	1,323	–	–	﹤0.01%	3185
2022 Q3	$19K	Hold	1,323	–	–	﹤0.01%	2798
2022 Q2	$13K	Buy	1,323 +73	+6%	+$805	﹤0.01%	2984
2022 Q1	$18K	Hold	1,250	–	–	﹤0.01%	2764
2021 Q4	$16K	Hold	1,250	–	–	﹤0.01%	2749
2021 Q3	$21K	Buy	1,250 +250	+25%	+$5.07K	﹤0.01%	2569
2021 Q2	$23K	Hold	1,000	–	–	﹤0.01%	2427
2021 Q1	$25K	Hold	1,000	–	–	﹤0.01%	2185
2020 Q4	$18K	Sell	1,000 -500	-33%	-$8.57K	﹤0.01%	2045
2020 Q3	$18K	Hold	1,500	–	–	﹤0.01%	1830
2020 Q2	$18K	Hold	1,500	–	–	﹤0.01%	1705
2020 Q1	$11K	Hold	1,500	–	–	﹤0.01%	1715
2019 Q4	$27K	Buy	+1,500	New	+$19.6K	﹤0.01%	1304

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Rockefeller Capital Management's KALV Position: Q1 2026 in Review

Rockefeller Capital Management increased its KalVista Pharmaceuticals (KALV) stake by 400% in Q1 2026, buying an estimated $8.57K and bringing the position to 665 shares worth $13.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3864.

Rockefeller Capital Management first reported a position in KALV in Q4 2019 and has held it in 15 quarters since. The position peaked at $27K in Q4 2019. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Rockefeller Capital Management held 665 shares of KalVista Pharmaceuticals worth $13.4K as of Q1 2026.
Rockefeller Capital Management bought 532 KalVista Pharmaceuticals shares in Q1 2026, an estimated $8.57K.
KalVista Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3864 holding.
Rockefeller Capital Management first reported a position in KalVista Pharmaceuticals in Q4 2019 and has held it in 15 quarters since.
Rockefeller Capital Management's KalVista Pharmaceuticals position peaked at $27K in Q4 2019.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.